glp 1 roche Ad hoc announcement pursuant to Art. 53 LR] announces positive Phase I results of its oral GLP-1 receptor agonist CT-996 for the treatment of people with obesity Roche's 22% Weight Loss Benefit

Patients exploring weight loss and metabolic support often encounter both berberine and GLP-1 medications in online discussions, leading to confusion about their roles

Key warnings include risk of thyroid C-cell tumors, pancreatitis, gallbladder disease, risk of acute kidney injury with severe gastrointestinal adverse reactions, and potential diabetic retinopathy complications

Peptide vaccine therapy in colorectal cancer

Whilst these effects are therapeutically beneficial for glycaemic control and weight reduction, they can potentially lead to reduced overall nutrient intake in some individuals

Pharmaceutics 16 , 651 (2024)